Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study will examine the safety, tolerability, and antiviral efficacy of sofosbuvir
(SOF)+ribavirin (RBV) in treatment-naive and treatment-experienced United States Veterans
with compensated cirrhosis and genotype 2 HCV infection.